A MULTICENTER CLINICAL TRIAL ON THE USE OF (–5, –7) PRO PROSTATE SPECIFIC ANTIGEN
Abstract
Purpose:
The determination of pro prostate specific antigen (proPSA) forms has been suggested to be promising in prostate cancer diagnosis. In this multicenter trial we evaluated the diagnostic usefulness of (-5, -7) proPSA.
Materials and Methods:
A total of 2,055 white men, including 1,046 with and 1,009 without prostate cancer, with total PSA (tPSA) between 0.28 and 81 ng/ml were retrospectively analyzed. Of these men 2,026 and 1,727 had tPSA less than 20 and less than 10 ng/ml, respectively. All subjects were untreated for prostatic disease and underwent multisector needle biopsy of the prostate. An Elecsys® 2010 analyzer was used to determine tPSA, free PSA (fPSA) and (-5, -7) proPSA in the 2,055 serum samples. ROC analyses were performed to discriminate men with biopsy positive and negative results in the entire and in select tPSA ranges.
Results:
In the select tPSA range 2 to 4 ng/ml the area under the ROC curve for proPSA (0.53) and proPSA/fPSA (0.59) was not significantly larger than that for tPSA (0.60) or the fPSA/tPSA (f/tPSA) ratio (0.64). In the tPSA range 4 to 10 ng/ml the area under the curve for the ratio proPSA/fPSA (0.67) was larger than for tPSA (0.53) but not larger than for f/tPSA (0.69). The f/tPSA ratio demonstrated the best discriminatory power in this tPSA range of 4 to 10 ng/ml.
Conclusions:
In this multicenter study no improvement in diagnostic accuracy was shown when comparing (-5, -7) proPSA and the corresponding ratios with tPSA or f/tPSA. Further studies using other proPSA forms or tumor associated proteins should be done.
References
- 1 : A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA1995; 273: 289. Google Scholar
- 2 : Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol1999; 162: 293. Link, Google Scholar
- 3 : Cancer statistics, 2004. CA Cancer J Clin2004; 54: 8. Google Scholar
- 4 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Google Scholar
- 5 : A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res1991; 51: 222. Google Scholar
- 6 : The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int2004; 93: 720. Google Scholar
- 7 : Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem1995; 41: 1567. Google Scholar
- 8 : “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology2000; 55: 41. Google Scholar
- 9 : Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol1997; 157: 2166. Link, Google Scholar
- 10 : Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem2001; 47: 1415. Google Scholar
- 11 : Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res2001; 61: 957. Google Scholar
- 12 : A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res2001; 61: 6958. Google Scholar
- 13 : A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res2000; 60: 756. Google Scholar
- 14 : Free prostate-specific antigen in serum is becoming more complex. Urology2002; 59: 797. Google Scholar
- 15 : Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem2004; 50: 1017. Google Scholar
- 16 : A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol2003; 170: 1175. Link, Google Scholar
- 17 : Software for illustrative presentation of basic clinical characteristics of laboratory tests—GraphROC for Windows. Scand J Clin Lab Invest Suppl1995; 222: 69. Google Scholar
- 18 : Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. Clin Chem1998; 44: 685. Google Scholar
- 19 : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol2004; 171: 2239. Link, Google Scholar
- 20 : Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol2003; 170: 2181. Link, Google Scholar
From the Departments of Urology, University Hospital Charité, Humboldt University Berlin (ML, CA, CS, DS, SAL, KJ), Berlin, Prostate Center, University Hospital (AS), Münster and University Hospital Eppendorf (MG, AH, FC), Hamburg, Germany, and Kantonsspital Aarau (MK), Aarau, Switzerland
